Conference Reports for NATAP

(IDRW) International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 4-8, 2013; Toronto, ON, Canada Back

Analysis and Characterization of treatment-Emergent Resistance in ART-Experienced, Integrase Inhibitor-Naïve Subjects With Dolutegravir (DTG) vs Raltegravir (RAL) in SAILING (ING111762)       Reported by Jules Levin (IDRW) International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 4-8, 2013; Toronto, ON, Canada   CROI: Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) - (03/06/13)   CROI: Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks - written by Mark Mascolini - (03/06/13)   CROI: Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results - (03/06/13)   Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study - (03/01/13)   CROI: SINGLE AND MULTIPLE DOSE DOLUTEGRAVIR PHARMACOKINETICS IN THE GENITAL TRACT AND COLORECTUM OF HIV NEGATIVE MEN AND WOMEN - (04/04/13)   CROI: Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals - (03/16/13)   Mark Underwood et al, GlaxoSmithKline